Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

CAR-T Cell Therapy: the Efficacy and Toxicity Balance

Toxicity and management in CAR T-cell therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Mechanisms and management of CAR T toxicity

Toxicities and related improvements of CAR-T Cell in the treatment of cancer

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up

Toxicity of Chimeric Antigen Receptor T Cells and Its Management

Reactions Related to CAR-T Cell Therapy

CAR-T Cell Therapy: Where Are We Now, and Where Are We Heading?

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Current progress in CAR-T cell therapy for tumor treatment

Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities

Current Clinical Application of the CAR-T Cell Therapy

CAR-T cell therapy: current limitations and potential strategies

From bench to bedside: the history and progress of CAR T cell therapy

Optimization Strategies in CAR T-cell Therapy: A Comprehensive Evaluation of Cytopenia, HLH/MAS, and Other Adverse Events

Current state of CAR-T therapy for T-cell malignancies

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy